
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).
МНЕНИЕ
Терапевтические стратегии для лечения болезни Вильсона–Коновалова: современное состояние и перспективы
Российский научно-исследовательский медицинский университет имени Н. И. Пирогова, Москва, Россия
Для корреспонденции: Арина Геннадиевна Шохина
ул. Островитянова, д. 1, стр. 1, г. Москва, 117513, Россия; ur.xednay@anihkohs.g.a
Финансирование: работа поддержана денежными средствами гранта Российского научного фонда (грант РНФ №24-74-10106).
Вклад авторов: А. В. Иваненко, В. Д. Стародубова — написание статьи; А. Г. Шохина — разработка концепции, написание и редактирование статьи, получение финансирования.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s disease. Journal of Hepatology. 2012; 56 (3): 671–85. DOI: 10.1016/j.jhep.2011.11.007.
- Weiss KH, et al. Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease. Gastroenterology. 2011; 140 (4): 1189–98.e1. DOI: 10.1053/j.gastro.2010.12.034.
- Munk DE, et al. Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study. Sci Rep. 2022; 12 (1): 14714. DOI: 10.1038/s41598-022-18872-8.
- Solovyev N, Ala A, Schilsky M, Mills C, Willis K, Harrington CF. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry. Analytica Chimica Acta. 2020; 1098: 27–36. DOI: 10.1016/j.aca.2019.11.033.
- Snijders RJALM, et al. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. Journal of Hepatology. 2024; 80 (4): 576–85. DOI: 10.1016/j.jhep.2023.11.032.
- Medici V, Sturniolo GC. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs. 2008; 11 (8): 592–606.
- Fujiyoshi J, et al. Therapeutic potential of hepatocyte-like-cells converted from stem cells from human exfoliated deciduous teeth in fulminant Wilson’s disease. Sci Rep. 2019; 9 (1): 1535. DOI: 10.1038/s41598-018-38275-y.
- Sauer V, et al. Repeated transplantation of hepatocytes prevents fulminant hepatitis in a rat model of Wilson’s disease. Liver Transplantation. 2012; 8 (2): 248–59. DOI: 10.1002/lt.22466.
- Leng Y, et al. Long-Term Correction of Copper Metabolism in Wilson’s Disease Mice with AAV8 Vector Delivering Truncated ATP7B. Human Gene Therapy. 2019; 30 (12): 1494–504. DOI: 10.1089/hum.2019.148.
- Murillo O, et al. Liver Expression of a MiniATP7B Gene Results in Long–Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice. Hepatology. 2019; 70 (1): 108–26. DOI: 10.1002/hep.30535.
- Pöhler M, et al. CRISPR/Cas9-mediated correction of mutated copper transporter ATP7B. PLoS ONE. 2020; 15 (9): e0239411. DOI: 10.1371/journal.pone.0239411.
- Fontana M, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025; 392 (1): 33–44. DOI: 10.1056/NEJMoa2409134.
- Gillmore JD, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021; 385 (6): 493–502. DOI: 10.1056/NEJMoa2107454.
- Baxter M, et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. Journal of Hepatology. 2015; 62 (3): 581–9. DOI: 10.1016/j.jhep.2014.10.016.
- Suominen S, et al. Improvements in Maturity and Stability of 3D iPSC-Derived Hepatocyte-like Cell Cultures. Cells. 2023; 12 (19): 2368. DOI: 10.3390/cells12192368.